FDA Panel Votes 17-6 Obesity Drugmakers Should Study Heart Risks; Watch Orexigen (OREX, VIVUS (VVUS), Arena (ARNA)
Tweet
Share
E-mail
Get Alerts OREX Hot Sheet
Join SI Premium – FREE
An FDA panel has just voted 17-6 that obesity drugmakers should study heart risks.
Traders should watch Orexigen (Nasdaq: OREX), VIVUS (Nasdaq: VVUS) and Arena (Nasdaq: ARNA).
UPDATE: Orexigen shares closed down 1 percent, VIVUS shares closed up 4 percent, and Arena shares closed up 4 percent.
Traders should watch Orexigen (Nasdaq: OREX), VIVUS (Nasdaq: VVUS) and Arena (Nasdaq: ARNA).
UPDATE: Orexigen shares closed down 1 percent, VIVUS shares closed up 4 percent, and Arena shares closed up 4 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- LiveRamp shrinks board to six directors after resignation
- Firm Capital Apartment REIT posts Q2 loss, plans name change
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
